New KRAS-Targeting Pill Nearly Doubled Survival in Advanced Pancreatic Cancer Trial

A once-daily pill targeting key KRAS mutations has nearly doubled median survival among patients with advanced pancreatic cancer, according to new clinical trial results presented in the United States. The findings offer cautious optimism in the fight against one of the world's deadliest cancers.

The experimental drug, daraxonrasib, developed by Revolution Medicines, was evaluated in 500 people with metastatic pancreatic cancer whose disease had progressed despite previous treatment. Participants were randomly assigned to receive either daraxonrasib or additional chemotherapy.

Patients treated with daraxonrasib achieved a median overall survival of 13.2 months, compared with 6.7 months for those receiving further chemotherapy. In a disease where survival is often measured in months, oncologists say an improvement of this magnitude represents a meaningful clinical advance.

Researchers also reported that patients receiving daraxonrasib generally experienced fewer severe side effects than those treated with standard chemotherapy. Participants remained on treatment for longer and reported less pain and a better quality of life, while many tumors either shrank or remained stable.

Why the New Drug Matters

Pancreatic cancer is notoriously difficult to detect in its early stages and often spreads before causing recognizable symptoms. According to the American Cancer Society, the United States is expected to see approximately 67,000 new cases and more than 52,000 deaths in 2024, while the overall five-year survival rate remains around 13 percent.

Unlike several other common cancers that have benefited from targeted therapies and immunotherapy, pancreatic cancer has remained largely resistant to many newer treatment approaches. For years, progress has been limited to incremental improvements achieved through combinations of conventional chemotherapy drugs.

Daraxonrasib is designed to block mutated forms of the KRAS protein, which normally regulates cell growth but can drive cancer development when altered. More than 90 percent of pancreatic cancers harbor KRAS mutations, making the protein an attractive—but historically difficult—therapeutic target.

For decades, KRAS was widely considered "undruggable" because its relatively smooth molecular surface made it difficult for medicines to bind effectively enough to inhibit its activity. Daraxonrasib employs what researchers describe as a molecular glue strategy, allowing it to bind multiple KRAS subtypes and disrupt their signaling.

Clinical Trial Details and Safety

The phase 3 trial enrolled patients with metastatic pancreatic cancer whose disease had progressed after standard first-line or second-line chemotherapy. By randomly assigning participants to receive either daraxonrasib or additional chemotherapy, the investigators were able to directly compare survival outcomes and treatment safety.

In addition to improving median overall survival, many patients receiving daraxonrasib remained on treatment at the time of the data cut-off, suggesting that the survival benefit could increase with longer follow-up. Measures of quality of life, including pain and daily functioning, also favored daraxonrasib over chemotherapy.

The most commonly reported side effects associated with daraxonrasib were skin rash, which could occasionally be severe, and mouth sores. According to the investigators, these adverse effects were generally manageable through dose adjustments and supportive care, and fewer patients discontinued treatment compared with those receiving chemotherapy.

Independent oncology specialists who were not involved in the study described the findings as a potentially important milestone. However, they emphasized that daraxonrasib is not a cure for pancreatic cancer and that tumors are still likely to develop resistance over time, making future combination therapies an important area of research.

Regulatory Path and Future Research

Revolution Medicines funded the trial and has submitted the results to the U.S. Food and Drug Administration for expedited review. The agency has also opened an expanded access program, allowing some eligible patients to receive daraxonrasib before a formal regulatory decision is made.

Oncologists report increased interest from patients and their families following the release of the early clinical data and patient experiences, highlighting the urgent need for additional treatment options. Experts caution, however, that access to the drug will remain limited until the regulatory review is complete and official prescribing guidance is established.

Researchers are planning additional studies to evaluate daraxonrasib earlier in the course of treatment, including trials involving newly diagnosed metastatic pancreatic cancer and patients with localized disease whose tumors may become operable if they respond to treatment. Additional studies are also investigating combinations with chemotherapy and immunotherapy.

Scientists also hope to determine whether specific KRAS mutation subtypes respond more favorably than others, potentially allowing treatment to become increasingly personalized. At the same time, other experimental therapies targeting individual KRAS variants are already in development, expanding the range of potential treatment options for pancreatic cancer.

Broader Efforts to Improve Pancreatic Cancer Care

The encouraging results for daraxonrasib come alongside other emerging approaches, including personalized cancer vaccines designed to recognize tumor-specific neoantigens and reduce the risk of recurrence after surgery. Early-stage clinical trials have reported multi-year survival in some patients considered to be at high risk.

Researchers are also studying advances in medical imaging, blood-based biomarkers, and genetic profiling to improve early diagnosis and better match patients with appropriate clinical trials. Experts believe that combining earlier detection with more effective targeted therapies could gradually improve survival rates over the coming decade.

For now, specialists continue to emphasize the importance of participation in clinical trials, given the limited standard treatment options and aggressive nature of pancreatic cancer. They hope that the success of this first broadly active KRAS-targeting pill will stimulate further investment and accelerate innovation in a field that has historically lagged behind many other areas of cancer research.

The findings were presented at the annual meeting of the American Society of Clinical Oncology in Chicago and published in a leading medical journal. If future research confirms these results, daraxonrasib could become a new standard treatment for patients with previously treated metastatic pancreatic cancer.